Intel prices an upsized common stock offering, raising $20 billion via a large underwritten deal

Intel said on Tuesday that it has priced an upsized registered public offering of common stock, a transaction designed to generate $20 billion in gross proceeds. The company’s announcement follows an earlier disclosure of a similar offering that was later expanded.

According to Intel’s pricing release, the deal will be an underwritten public offering of 210,526,315 shares of common stock. Intel did not describe in its short pricing announcement the per-share public offering price or the full list of terms in the text provided, but it confirmed the share count and the total offering size.

The company framed the move as a standard capital markets step tied to a widely used SEC registration process. A “registered public offering” means the securities are offered pursuant to a registration statement reviewed by regulators, rather than through a private sale or an exemption that limits the investor base. An “underwritten” offering means investment banks agree to purchase shares from the issuer and then resell them to investors, helping to set distribution and demand expectations.

Intel has previously relied on large equity and debt issuance windows to fund long-term capacity, technology development, and other corporate needs as the semiconductor industry cycles through major investment rounds. Equity issuance can also strengthen a company’s balance sheet while limiting the immediate cash costs associated with additional debt, though it can dilute existing shareholders.

For investors, the headline variable in a priced offering is typically the economics, including the offering price and the discounts versus recent trading levels, which determine both dilution and the demand the underwriting syndicate can place with institutional buyers. Intel’s announcement in the provided text confirms the size and the share count but does not include those pricing-economics details.

Intel also did not specify in the provided text how it expects to allocate the net proceeds, the expected closing date, or whether the underwriters will have an option to purchase additional shares to cover over-allotments. Those items are usually set out in the prospectus supplement and related offering documents, which were not included in the materials available here.